C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
出版年份 2020 全文链接
标题
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma
作者
关键词
-
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 86, Issue 1, Pages 75-85
出版商
Springer Science and Business Media LLC
发表日期
2020-06-14
DOI
10.1007/s00280-020-04088-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Current status of prognostic factors in patients with metastatic renal cell carcinoma
- (2019) Jun Teishima et al. INTERNATIONAL JOURNAL OF UROLOGY
- Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer—A protocol for systematic review and meta-analysis
- (2019) Chellan Kumarasamy et al. MEDICINE
- Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
- (2019) Hiroki Ishihara et al. Targeted Oncology
- C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab
- (2019) Kotaro Suzuki et al. International Journal of Clinical Oncology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cachectic Cancer Patients: Immune to Check-point Inhibitor Therapy?
- (2018) Christopher C Coss et al. CLINICAL CANCER RESEARCH
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor
- (2018) Norikazu Matsuo et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
- (2017) Markus V. Heppt et al. EUROPEAN JOURNAL OF CANCER
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
- (2017) Jun Teishima et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis
- (2017) Jie-Hui Zhong et al. Oncotarget
- Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
- (2017) Yuko Oya et al. Oncotarget
- Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- (2017) Ghayathri Jeyakumar et al. Journal for ImmunoTherapy of Cancer
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma
- (2015) Jun Teishima et al. BJU INTERNATIONAL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
- (2012) Hiroki Ito et al. BMC CANCER
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
- (2012) Donald C. McMillan CANCER TREATMENT REVIEWS
- Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
- (2011) Kristine H. Allin et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients
- (2009) Sei Naito et al. EUROPEAN UROLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
- (2009) T.V. Johnson et al. JOURNAL OF UROLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma
- (2008) Kazutaka Saito et al. EUROPEAN UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started